XFOR logo

XFORX4 Pharmaceuticals Inc

$3.83
$0.18
(4.49%)
Today
Closed $3.83
$0.07
(1.83%)
After Hours
Updated: 07:28 PM EDT
Mkt Cap$378.22M
Vol447,735.00
News
all
press releases
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
News Placeholder
More News
News Placeholder
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now...
Yahoo! Finance: News
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative...
MarketBeat
News Placeholder
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +11.86% and -67.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
X4 Pharmaceuticals (XFOR) to Release Earnings on Thursday
X4 Pharmaceuticals (NASDAQ:XFOR) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Trading Up 0.7% - Time to Buy?
X4 Pharmaceuticals (NASDAQ:XFOR) Trading 0.7% Higher - Here's Why...
MarketBeat
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat.com...
MarketBeat
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.